Coronary/Structural Heart

Nuwellis Announces Peer-Reviewed Publication of Clinical Trials Analysis Advocating the Use of Ultrafiltration for Heart Failure Patients Resistant to Diuretics

MINNEAPOLIS, March 21, 2023 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced the peer-reviewed publication of an analysis of available ultrafiltration clinical trials with findings that support ultrafiltration as a safe and effective therapeutic option […]

Biometrics Leader LifeQ Revolutionizes Healthcare with Disease Screening and Early Detection

Clinical-grade biometric data flags chronic and acute diseases and disorders—assisting clinicians, improving health and wellness, and bettering lives ATLANTA, March 20, 2023 /PRNewswire/ — LifeQ, the company that uses globally-recognized watch brands to gather personalized, clinical-grade data, announced it can detect as many as 40 sleep and cardiovascular disorders with smart watches […]

MyOme Presents New Data on an Integrated Polygenic Risk Score to Improve Coronary Artery Disease Prediction at the American College of Medical Genetics and Genomics Annual Meeting

Integrated polygenic risk score can more accurately identify people at high risk of developing coronary artery disease across diverse ancestries over a commonly used clinical tool. MENLO PARK, Calif., March 16, 2023 /PRNewswire/ — MyOme, Inc., a clinical whole genome platform analysis company and a leader in the development of polygenic risk scores with […]

Reconstituted Amarin Board Ready for the Challenge of Unlocking True Potential of VASCEPA®/VAZKEPA® (Icosapent Ethyl)

New Amarin Board Believes the Company Will Thrive with Proper Stewardship New Amarin Directors are Working with Urgency to Address Issues at Amarin DUBLIN, Ireland and BRIDGEWATER, N.J., March 16, 2023 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ: AMRN) today released the following statement: Since joining the company two weeks […]

New Study Demonstrates Accurate Measurement of Left Ventricular Function Following Treatment with BioVentrix Revivent TC® Therapy

Inward Displacement Approach Assesses HFrEF Patients for Left Ventricular Device Therapy MANSFIELD, Mass., March 15, 2023 /PRNewswire/ — BioVentrix®, Inc., a privately held medical device company developing less invasive therapies to directly treat the dilated left ventricle leading to progressive heart failure, today announced the publication of a peer-reviewed paper in the Journal of Clinical Medicine, […]

Over 1,000 Patients Enrolled in Landmark SELUTION DeNovo Study

GENEVA, March 15, 2023 /PRNewswire/ — MedAlliance has announced enrollment of over 1,000 patients in its ground-breaking SELUTION DeNovo coronary randomized study. Recruitment is now a third of the way towards the target of 3,326 patients. SELUTION DeNovo compares the treatment strategy using a novel sirolimus drug-eluting balloon [DEB SELUTION], versus a limus […]

Philips and Gibraltar Health Authority announce 16-year strategic partnership, transforming patient imaging and cardiac care at St Bernard’s Hospital

March 07, 2023 For the first time, patients will no longer need to travel abroad for treatment of acute cardiac diseases, as the Gibraltar Health Authority prepares to provide local coronary angiography and angioplasty services in a new interventional cardiac suite Amsterdam, the Netherlands and Gibraltar – Royal Philips (NYSE: PHG, AEX: […]

Karolinska Development’s portfolio company AnaCardio’s founder publishes article that supports development of heart failure drug candidate AC01

STOCKHOLM, SWEDEN March 14, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that the founder of its portfolio company AnaCardio, Professor Lars Lund, has published an article on a heart failure study in the scientific journal European Heart Journal. The study’s publication reinforces the company’s efforts to develop a […]